Skip to main content

SYNERON MEDICAL LTD Value Stock - Dividend - Research Selection


ISIN: IL0010909351, WKN: A0B7YM

Market price date: 30.11.-0001
Market price: 0,00 USD

SYNERON MEDICAL LTD Fundamental data and company key figures of the share

Annual reports in USD
Key figures 23-03-2017
Cash flow
Net operating cash flow 8.360.000
Capital Expenditures -3.849.000
Free cash flow 4.511.000
Balance sheet
Total Equity 207.420.000
Liabilities & Shareholders equity 277.185.000
Income statement
Net income 179.000
Eps (diluted) 0,010
Diluted shares outstanding 34.945.000
Net sales/revenue 298.102.000

Fundamental ratios calculated on: 30-11--0001

Key figures 30-11--0001
Cash flow
P/C 0,00
P/FC 0,00
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization384.395.008,00 USD
Raw Data Source
Stock Split

Description of the company

Syneron Medical Ltd., designs, develops and markets aesthetic medical products based on its various technologies including its Electro-Optical Synergy (ELOS), technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments. The Company´s products, which it sells primarily to physicians and other practitioners, target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin´s appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference and laser-assisted lipolysis. On February 13, 2012, the Company acquired Ultrashape Ltd. On March 14, 2012, Syneron acquired substantially all the assets of TransPharma Medical Ltd.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,